论文部分内容阅读
应用阿克拉霉素 (ACR)、吡柔比星 (THP)为主的方案治疗恶性淋巴瘤各 2 1例及 33例 ,两组对照表明 :阿克拉霉素有效率 81 .0 % ,吡柔比星有效率 94.0 % ,吡柔比星疗效高于阿克拉霉素但并无显著差别 ,P>0 .0 5 ;副作用方面 ,二者对肝肾功能影响均小 ,在脱发及对心脏毒性方面二药无显著差别 ,P>0 .0 5 ;阿克拉霉素胃肠道反应及口腔粘膜溃疡发生率高于吡柔比星 ,P≤ 0 .0 5 ;但吡柔比星骨髓抑制发生率高于阿克拉霉素 ,P≤ 0 .0 5 ;提示二药副作用的发生各有不同特点。
The treatment of malignant lymphoma with acridinemycin (ACR) and pirarubicin (THP)-based regimens was performed in 21 cases and 33 cases respectively. The control of the two groups showed that the effective rate of aclacinomycin was 81.0%, and Pirou The effective rate of STAR was 94.0 %. The efficacy of pirarubicin was higher than that of aclarubicin, but there was no significant difference, P> 0.05. In terms of side effects, both had little effect on liver and kidney function, and they were less sensitive to alopecia and cardiotoxicity. There was no significant difference between the two drugs, P>0.05; the incidence of gastrointestinal reactions and oral mucosal ulcers of aclamycin was higher than that of pirarubicin, P≤0.05, but pirarubicin bone marrow suppression occurred. The rate is higher than that of aclarubicin, P ≤ 0.05, suggesting that the occurrence of the side effects of the two drugs have different characteristics.